Risk Factors Update Summary

• Increased risks related to data security breaches, unauthorized access to customer data, potential litigation, and regulatory risks. This change might result in financial losses and reputational damage.
• Risks related to disruptions in the supply chain, including the need to purchase key raw materials and components for manufacturing operations. This change could impact operational efficiency and financial performance.
• Added an effective system of internal controls over financial reporting to prevent misstatements.
• Transition from exploring to pursuing new product technologies and applications, including integrating Nebula's whole genome sequencing services. This change indicates a strategic shift in product development.
• Introduction of risks related to the integration of machine learning and AI technology, highlighting operational, compliance, and reputational risks. This change underscores the potential impact on business operations and results.
• Risks related to drug development operations, particularly the early stage of product candidates in pre-clinical development. This change indicates a long timeline before potential commercialization and revenue generation.
• Identified material weaknesses in controls, including inadequate review and errors in financial reporting.
• Addition of risks related to unfavorable global economic conditions, geopolitical events, and bank failures affecting financial services industry. This change highlights potential adverse impacts on business operations and financial condition.
• Risks associated with contract manufacturing and dietary supplement business, including disruptions at manufacturing facilities and regulatory challenges. This change emphasizes potential adverse effects on business operations and prospects.
• Material weaknesses in internal controls may lead to inaccurate financial reporting and potential restatements.
• CEO ownership increased from 18% to 20% of common stock, potentially limiting control.
• CEO beneficial ownership disclosed as approximately 20% of common stock, up from 18%.
• Provisions in Bylaws and Certificate of Incorporation may deter takeover attempts.
• Added provisions in Bylaws and Certificate of Incorporation to deter takeover attempts.